



Epigenomic reprogramming of therapy-resistant circulating tumor cells in colon cancer

Aida Bao-Caamano, Nicolás Costa-Fraga, Laure Cayrefourcq, Aitor Rodriguez-Casanova, Laura Muinelo-Romay, Rafael López-López, Catherine Alix-Panabières, Angel Díaz-Lagares

► To cite this version:

Aida Bao-Caamano, Nicolás Costa-Fraga, Laure Cayrefourcq, Aitor Rodriguez-Casanova, Laura Muinelo-Romay, et al.. Epigenomic reprogramming of therapy-resistant circulating tumor cells in colon cancer. *Frontiers in Cell and Developmental Biology*, 2023, 11, pp.1291179. <10.3389/fcell.2023.1291179>. <hal-04948383>

HAL Id: hal-04948383

<https://hal.science/hal-04948383v1>

Submitted on 14 Feb 2025

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY 4.0 - Attribution - International License



OPEN ACCESS

EDITED BY

Li Min,
Capital Medical University, China

REVIEWED BY

Xiguang Xu,
Virginia Tech, United States
Rauf Ahmad Najar,
University of Rochester, United States

*CORRESPONDENCE

Angel Díaz-Lagares,
✉ angel.diaz.lagares@sergas.es
Catherine Alix-Panabières,
✉ c-panabieres@chu-montpellier.fr
Rafael López-López,
✉ rafael.lopez.lopez@sergas.es

†These authors have contributed equally to this work

RECEIVED 08 September 2023

ACCEPTED 28 November 2023

PUBLISHED 21 December 2023

CITATION

Bao-Caamano A, Costa-Fraga N, Cayrefourcq L, Rodríguez-Casanova A, Muínelo-Romay L, López-López R, Alix-Panabières C and Díaz-Lagares A (2023), Epigenomic reprogramming of therapy-resistant circulating tumor cells in colon cancer.

Front. Cell Dev. Biol. 11:1291179.
doi: 10.3389/fcell.2023.1291179

COPYRIGHT

© 2023 Bao-Caamano, Costa-Fraga, Cayrefourcq, Rodríguez-Casanova, Muínelo-Romay, López-López, Alix-Panabières and Díaz-Lagares. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Epigenomic reprogramming of therapy-resistant circulating tumor cells in colon cancer

Aida Bao-Caamano^{1,2,3}, Nicolás Costa-Fraga^{1,2,3}, Laure Cayrefourcq^{4,5}, Aitor Rodríguez-Casanova^{1,2,3,6}, Laura Muínelo-Romay^{3,7,8}, Rafael López-López^{3,6,8,9*†}, Catherine Alix-Panabières^{4,5,10*†} and Angel Díaz-Lagares^{1,3,8,11*†}

¹Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain, ²Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain, ³Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain, ⁴Laboratory of Rare Human Circulating Cells—The Liquid Biopsy Lab, University Medical Center of Montpellier, Montpellier, France, ⁵Centre for Ecological and Evolutionary Cancer Research, Maladies infectieuses et vecteurs: génétique, évolution et contrôle, University of Montpellier, CNRS, IRD, Montpellier, France, ⁶Roche-Chus Joint Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain, ⁷Liquid Biopsy Analysis Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain, ⁸Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain, ⁹Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain, ¹⁰European Liquid Biopsy Society (ELBS), Hamburg, Germany, ¹¹Department of Clinical Analysis, University Hospital Complex of Santiago de Compostela (CHUS), Santiago de Compostela, Spain

Therapy resistance is a major challenge in colorectal cancer management. Epigenetic changes, such as DNA methylation, in tumor cells are involved in the development of acquired resistance during treatment. Here, we characterized the DNA methylation landscape of colon circulating tumor cells (CTCs) during cancer progression and therapy resistance development. To this aim, we used nine permanent CTC lines that were derived from peripheral blood samples of a patient with metastatic colon cancer collected before treatment initiation (CTC-MCC-41) and during treatment and cancer progression (CTC-MCC-41.4 and CTC-MCC-41.5 [A-G]). We analyzed the DNA methylome of these nine CTC lines using EPIC arrays and also assessed the association between DNA methylation and gene expression profiles. We confirmed DNA methylation and gene expression results by pyrosequencing and RT-qPCR, respectively. The global DNA methylation profiles were different in the pre-treatment CTC line and in CTC lines derived during therapy resistance development. These resistant CTC lines were characterized by a more hypomethylated profile compared with the pre-treatment CTC line. Most of the observed DNA methylation differences were localized at CpG-poor regions and some in CpG islands, shore regions and promoters. We identified a distinctive DNA methylation signature that clearly differentiated the pre-treatment CTC line from the others. Of note, the genes involved in this signature were associated with cancer-relevant pathways, including PI3K/AKT, MAPK, Wnt signaling and metabolism. We identified several epigenetically deregulated genes associated with therapy resistance in CTCs, such

as *AP2M1*. Our results bring new knowledge on the epigenomic landscape of therapy-resistant CTCs, providing novel mechanisms of resistance as well as potential biomarkers and therapeutic targets for advanced CRC management.

KEYWORDS

Epigenomics, DNA methylation, metastasis-competent CTCs, colorectal cancer, biomarkers, therapeutic targets, therapy resistance

1 Introduction

Colorectal cancer (CRC) is the third most frequent cancer and the second leading cause of cancer-related mortality worldwide (Sung et al., 2021). Up to 50% of patients with CRC present metastases at diagnosis or develop metastases during the disease course (Biller and Schrag, 2021). Despite recent advances in treatment regimens, fluoropyrimidine-based chemotherapy continues to be frequently used for metastatic CRC (mCRC). However, tumors quickly fail to respond due to the development of resistance (Narayan et al., 2022).

Analysis of liquid biopsy analytes, such as circulating tumor cells (CTCs), has demonstrated clinical utility for the non-invasive evaluation of the therapy response. Indeed, CTC enumeration can provide information about CRC progression and therapy response (Aranda et al., 2020). Moreover, nine CTC lines generated from blood samples of a patient with mCRC in Alix-Panabières' laboratory allow studying therapy-driven tumor changes (Soler et al., 2018). This series of nine colon CTC lines were established from peripheral blood samples collected from the same patient at different time-points during the disease course: i) before the first treatment (CTC-MCC-41 line) (Cayrefourcq et al., 2015) and ii) after treatment: CTC-MCC-41.4 line (after first-line FOLFIRI/bevacizumab and second-line FOLFOX/bevacizumab), and 7 cell lines (CTC-MCC-41.5 [A-G]) established from blood collected 1 week before the patient's death. The cell lines CTC-MCC-41.5 [A-G] were originated from the same blood sample after proliferating *in vitro* independently at different time points and exhibiting different morphological features (Soler et al., 2018). Of note, the transcriptomic analysis of all these CTC lines revealed that treatment pressure can induce changes in their gene expression profiles associated with therapy resistance, indicating that the molecular profiling of these CTC lines is a relevant approach to study disease progression and discover new biomarkers of therapy resistance (Cayrefourcq et al., 2021).

Some studies demonstrated that CTCs are characterized by DNA methylation profile alterations that promote metastasis formation (Chimonidou et al., 2011; Gkoutela et al., 2019). DNA methylation is based on the incorporation of a methyl group into the cytosine of cytosine-phosphate-guanine (CpG) dinucleotides. This epigenetic modification usually occurs in the context of high density CpG dinucleotides, called CpG islands (CpGIs). However, DNA methylation can also occur in regions with lower CpG density that flank CpGIs (CpG shores) (Rodriguez-Casanova et al., 2021). In cancer, aberrant DNA methylation in CpGIs and shores of promoters is usually associated with changes in gene expression, with a negative correlation between DNA methylation and gene expression (Diaz-Lagares et al., 2016; Tan et al., 2019). Of note, DNA methylation alterations in CRC are closely related to cancer progression and chemotherapy resistance

(Moutinho et al., 2014; Diaz-Lagares et al., 2016). However, no study investigated whether DNA methylation changes in colorectal CTCs are associated with cancer progression and therapy resistance.

Therefore, in this work, we used a genome-wide DNA methylation analysis to compare the DNA methylation landscape of the previously described nine colon CTC lines with the aim of obtaining new biological information and identifying biomarkers and therapeutic targets linked to CRC progression and therapy resistance.

2 Materials and methods

2.1 Cancer cell lines

The nine colon CTC lines used in this work (CTC-MCC-41, CTC-MCC-41.4, CTC-MCC-41.5A, CTC-MCC-41.5B, CTC-MCC-41.5C, CTC-MCC-41.5D, CTC-MCC-41.5E, CTC-MCC-41.5F and CTC-MCC-41.5G) have been previously characterized (Cayrefourcq et al., 2015; Soler et al., 2018). All CTC lines were cultured at 37°C and 5% CO₂ in ultra-low attachment flasks (Corning) with RPMI-1640 medium (Merck) supplemented with 10% fetal bovine serum (Merck), 1% penicillin/streptomycin solution (Gibco), 1% L-glutamine (Merck), 1% of Insulin-Transferrin-Selenium (ITS-G) (Gibco), basic human fibroblast growth factor (Miltenyi Biotec) at a final concentration of 10 ng/mL and human epidermal growth factor (Miltenyi Biotec) at a final concentration of 20 ng/mL.

2.2 DNA and RNA isolation from the nine CTC lines

Total genomic DNA was isolated from the nine CTC lines using a standard high salt method based on SDS/proteinase K. The isolated DNA was treated with RNase A (Qiagen) following the manufacturer's recommendations and stored at -80°C until analysis. All DNA samples were quantified with the Qubit 4 fluorometric method (Invitrogen) using the Qubit dsDNA BR (Broad Range) Assay Kit (Invitrogen). Total RNA was isolated from the CTC lines using TRIzol (Invitrogen) according to the manufacturer's protocol, quantified using a NanoDrop One spectrophotometer (Thermo Scientific), and stored at -80°C until analysis.

2.3 Genome-wide DNA methylation analysis by EPIC arrays

Total genomic DNA (500 ng) from three passages of the nine CTC lines was treated with sodium bisulfite using the EZ DNA

Methylation kit (Zymo Research). Following the manufacturer's protocol, the bisulfite-converted DNA was hybridized using the Infinium MethylationEPIC (EPIC) array that targets >850,000 CpG sites in the human genome (Moran et al., 2016). After methylation values were obtained in a HiScan System (Illumina), data were processed using RnBeads 2.0 (Muller et al., 2019). Raw intensity data (IDAT) files were imported into RnBeads 2.0 for quality control and preprocessing. First, the greedycut algorithm was used to filter out low-quality probes. Probes overlapping with single nucleotide polymorphisms and probes with sequences that mapped to multiple genomic locations (cross-reactive) were removed. Raw IDAT files were normalized using the beta-mixture quantile (BMIQ) method. DNA methylation was represented as the average β -value that was calculated as the ratio of the fluorescence signal intensity of the methylated probe to the signals of all (methylated and unmethylated) probes. The average β -values were used to calculate the mean DNA methylation difference between groups. Hierarchical linear models performed with RnBeads 2.0 were used to determine the DNA methylation differences between groups. p -values were corrected for multiple testing (FDR) using the Benjamini–Hochberg method and a p -value <0.05 was selected for significance. Heatmaps of β -values were generated using unsupervised hierarchical clustering and the Complex Heatmap package. GeneCodis was used for Gene Ontology (GO) enrichment and Panther pathway analyses (Tabas-Madrid et al., 2012).

2.4 Locus-specific DNA methylation analysis by pyrosequencing

Total genomic DNA (500 ng) from three passages of the nine CTC cell lines was treated with sodium bisulfite with the EZ DNA Methylation kit (Zymo Research) following the manufacturer's recommendations. For pyrosequencing, primer sequences (Supplementary Table S1) were designed with PyroMark Assay Design 2.0 (Qiagen). Standard PCRs were carried out with bisulfite-converted genomic DNA. PCR products were analyzed on 2% agarose gels before pyrosequencing. A PyroMark Q24 Vacuum Workstation was used for the immobilization and preparation of PCR products. Pyrosequencing reactions were performed using a PyroMark Gold Q24 Reagent Kit (Qiagen) following the manufacturer's instructions. DNA methylation values were obtained using the PyroMark Q24 software 2.0 (Qiagen). Human methylated and non-methylated DNA samples (Zymo Research) were used as positive and negative control, respectively. Water was used as no-template control.

2.5 Gene expression analysis

Microarray expression data (Affymetrix HG-U133P) of the nine CTC cell lines were from a previous study by Cayrefourcq et al. (Cayrefourcq et al., 2021). For reverse transcription-quantitative PCR (RT-qPCR), the isolated RNA was first treated with DNase I using the Turbo DNA-free Kit (Invitrogen) according to the manufacturer's recommendations. Next, 1–2 μ g of RNA was retrotranscribed using the SuperScript First-Strand Synthesis

System for RT–PCR (Invitrogen). Reactions were performed in triplicate on a StepOne Plus system (Applied Biosystems) using 25–200 ng cDNA, 10 μ L Power SYBR Green PCR Master Mix (Applied Biosystems) and 0.3 μ L of the 10 μ M specific primers in a final volume of 20 μ L. Results were normalized to the expression level of β 2-microglobulin (endogenous control) in each sample. The primers used are listed in Supplementary Table S2.

2.6 Statistical analysis


Hierarchical linear models performed with RnBeads 2.0 were used to determine the DNA methylation differences between groups. p -values were corrected for multiple testing (FDR) using the Benjamini–Hochberg method and a p -value <0.05 was selected for significance. To compare DNA methylation data and gene expression values obtained by pyrosequencing and RT-qPCR, the data distribution normality was tested using the Kolmogorov–Smirnov test followed by the Mann–Whitney U test or the Student's t -test. The GraphPad Prism 8.0 software and the R statistical environment (version 4.2.0) were used for statistical analyses. All p -values were calculated with two-tailed tests and were considered significant when the p -value was <0.05.

3 Results

3.1 DNA methylation differences between the pre- and post-treatment CTC lines

The DNA methylation profiles of the pre-treatment CTC-MCC-41 line and of the eight post-treatment CTC lines (CTC-MCC-41.4 and CTC-MCC-41.5 [A–G]) were obtained using the EPIC array. After data normalization and quality control, 803,354 valid CpGs were selected for the analysis (Figure 1A). A scatter plot analysis revealed differences in the DNA methylation profiles of pre- and post-treatment CTC lines (Figure 1B). Specifically, this analysis identified 34,085 significantly differentially methylated CpGs (DMCpGs) (p -value <0.05; FDR adjusted p -value <0.05; $\Delta\beta$ -value >|0.20|) between CTC-MCC-41 and the eight post-treatment CTC lines, among which 4,018 DMCpGs were located in promoters and shore regions.

The 34,085 DMCpGs showed a wide distribution throughout the genome (Figure 1C). In pre-treatment CTC-MCC-41 cells, 63% of all DMCpGs (21,409 CpGs) were hypermethylated and 37% (12,676 CpGs) were hypomethylated compared with the post-treatment CTC lines (Figure 1D). Both hyper- and hypomethylated CpGs in CTC-MCC-41 cells showed a similar distribution (i.e., gene region location and CpG context) (Figure 1E). Most of these DMCpGs (64% of hyper- and 66% of hypo-methylated CpGs) were located in open sea regions, characterized by low CpG density. In gene regions, both hyper- and hypo-methylated CpGs were fairly homogeneously distributed throughout promoters, gene bodies, and intergenic regions. Moreover, DNA methylation differences were observed between CTC-MCC-41 and the post-treatment CTC lines in CpGs located at transcription factor binding sites (TFBS). Specifically, 2,369 CpGs were hypomethylated at TFBS (19% of all hypomethylated CpGs) and 3,591 CpGs were hypermethylated at TFBS (16% of all hypermethylated CpGs) in the CTC-MCC-41 line compared with



the other CTC lines. Moreover, a small percentage of DMCpGs (5% of hyper- and 3% of hypo-methylated CpGs in CTC-MCC-41 line) was located at enhancer regions.

A hierarchical clustering analysis using the 10,000 most differentially methylated CpGs showed that the DNA methylation profile could be used to clearly differentiate the pre- and post-treatment CTC lines (Figure 2A). The hierarchical clustering analysis also separated the post-treatment CTC lines in two branches: i) CTC-MCC-41.4 and CTC-MCC-41.5 [CDE] and ii) CTC-MCC-41.5 [ABFG]. Supplementary Table S3 lists the 20 top DMCpGs between pre- and post-treatment CTC lines. KEGG and Panther analyses revealed that the obtained methylation profile was enriched in pathways related to PI3K/AKT and MAPK signaling, metabolism, Wnt signaling, cadherin and integrin signaling, inflammation and apoptosis, among others (Figure 2B).


3.2 Comparison of the DNA methylation profiles of post-treatment CTC lines

First, the DNA methylation profiles of the CTC-MCC-41.4 (derived from a blood sample collected at the time of the second relapse at the end of second-line therapy) and the CTC-MCC-41.5 [A-G] (derived from a blood sample collected after the last cancer relapse, 1 week before the patient death) lines were compared (Soler et al., 2018). This

comparison identified only 4,475 DMCpGs (p -value <0.05 ; FDR adjusted p -value <0.05 ; $\Delta\beta$ -value $>|0.20|$) (Supplementary Figure S1A). Similarly, the scatter plot analysis revealed rather similar methylation patterns between the CTC-MCC-41.4 and the CTC-MCC-41.5 [A-G] lines (Supplementary Figure S1B). As our previous analysis revealed different DNA methylation profiles between the CTC-MCC-41.5 [ABFG] lines and the CTC-MCC-41.5 [CDE] lines (Figure 2A), the methylome of these two CTC groups were compared. This led to the identification of 43,863 DMCpGs (p -value <0.05 ; FDR adjusted p -value <0.05 ; $\Delta\beta$ -value $>|0.20|$) between the CTC-MCC-41.5 [ABFG] and CTC-MCC-41.5 [CDE] groups (Figure 3A). The scatter plot analysis also revealed a different DNA methylation pattern between these CTC groups (Figure 3B). The hierarchical clustering analysis of the 10,000 most DMCpGs between these groups revealed DNA methylation profiles that clearly differentiated the CTC-MCC-41.5 [ABFG] from the CTC-MCC-41.5 [CDE] lines (Figure 3C).

3.3 Association of the DNA methylation and transcriptional profiles in the pre- and post-treatment CTC lines

The transcriptional profiles of the pre-treatment CTC-MCC-41 and the post-treatment CTCs (CTC-MCC-41.4 and CTC-MCC-



41.5 [A-G]) lines were analyzed in a previous work (Cayrefourcq et al., 2021), revealing 6,327 differentially expressed transcripts between these CTC groups (1,857 up- and 4,470 downregulated in CTC-MCC-41 respect to the post-treatment CTCs). These expression data were used in this study to evaluate the association of gene expression with the DNA methylation changes observed in CpGs and shore regions of promoters. Particularly, as the CTC-MCC-41 line was more hypermethylated than the post-treatment CTC lines, this analysis focused on associations between DNA hypermethylated and downregulated genes in CTC-MCC-41 cells (Figure 4A). The Venn diagram showed that in the pre-treatment CTC-MCC-41 line, 319 genes were hypermethylated and transcriptionally silenced. Six of these genes (*AP2M1*, *FKBP11*, *GALNT6*, *BDNF*, *COL9A3* and *NR4A1*) were selected for validation based on the following criteria: i) high DNA methylation ($\Delta\beta$ -value ≥ 0.30 ; Supplementary Table S4) and high gene expression difference (fold change ≥ 2.0) between the CTC-MCC-41 and the post-treatment CTC lines; and ii) implication in cancer-relevant pathways. For all the CpGs and genes analyzed, the pyrosequencing analysis showed higher DNA methylation levels in the pre-treatment CTC-MCC-41 line than in all post-treatment CTC lines (Figure 4B). Similar results were obtained when the DNA methylation of each post-treatment CTC line was analyzed individually (Figure 4C). The negative association between the methylation and expression of all the selected genes was validated by RT-qPCR analysis, by comparing the gene expression from three hypomethylated post-treatment CTC lines with the hypermethylated CTC-MCC-41 line. As expected, all the genes showed significantly higher expression in the hypomethylated

post-treatment cell lines than in the hypermethylated pre-treatment cell line (Supplementary Figure S2). Altogether, these results confirm that the genes *AP2M1*, *FKBP11*, *GALNT6*, *BDNF*, *COL9A3*, and *NR4A*, are epigenetically regulated by methylation changes in the CTC lines analyzed.

3.4 Epigenetic regulation of *AP2M1* in the pre- and post-treatment CTC lines

Among the genes validated by pyrosequencing, *AP2M1* showed the highest DNA methylation differences between pre- and post-treatment CTC lines (Supplementary Table S4). Analysis of the pre- and post-treatment CTC lines revealed a negative association between the DNA methylation levels at the *AP2M1* promoter and its expression level (Figure 5A). Moreover, a negative correlation between DNA methylation and *AP2M1* expression was also observed when the paired values of the pre-treatment line and all post-treatment CTC lines were considered (Figures 5B, C). Among all post-treatment CTC lines, the CTC-MCC-41.5 [ABFG] lines were characterized by the lowest DNA methylation level at the *AP2M1* promoter.

4 Discussion

Epigenomic reprogramming is a hallmark of cancer that can induce broad epigenetic shifts in tumors (Hanahan, 2022) and promote the development of drug-resistance (Sawant et al.,




FIGURE 3

Genome-wide DNA methylation analysis of the post-treatment CTC-MCC-41.5 [ABFG] lines and CTC-MCC-41.5 [CDE] lines. **(A)** Approach used to identify significant DMCPGs in the CTC-MCC-41.5 [ABFG] lines compared with the CTC-MCC-41.5 [CDE] lines. **(B)** Scatter plot showing the mean normalized DNA methylation levels (β -values) in the CTC-MCC-41.5 [ABFG] and CTC-MCC-41.5 [CDE] lines. Red dots indicate significant DMCPGs. **(C)** Hierarchical clustering heatmap of the 10,000 most DMCPGs (FDR adjusted p -value < 0.05) in the CTC-MCC-41 [ABFG] lines compared with the CTC-MCC-41 [CDE] lines. QC, quality control; FDR, false discovery rate.

2023). Understanding the underlying mechanisms of resistance and identifying new biomarkers are necessary steps to improve the outcome of patients with CRC (Luo et al., 2021). To this aim, the molecular characterization of CTC lines has proven to be a relevant approach (Cayrefourcq et al., 2021). Here, we compared the DNA methylome of the pre-treatment CTC line CTC-MCC-41 and of eight post-treatment CTC lines (CTC-MCC-41.4 and CTC-MCC-41.5 [A-G]) that were established from blood samples of a patient with mCRC during disease progression and development of resistance to 5-fluorouracil-based therapy. This comparison showed that the DNA methylation profile of metastasis-competent CTCs is reprogrammed during cancer progression and therapy resistance development. These epigenetic changes were able to modulate the transcription process, restoring the expression of genes with pro-tumoral functions through hypomethylation. These results suggest that the epigenomic reprogramming observed in resistant CTCs could be a mechanism to favor the pro-tumoral properties of these cells and escape the action of the treatment, which would have negative consequences for the outcome of the disease. The epigenetically deregulated genes identified could also have impact in the clinic as non-invasive biomarkers for therapy resistance and novel therapeutic targets for CRC patients.

In our study, the post-treatment CTC lines derived during therapy resistance development showed a different global DNA

methylation profile compared with the pre-treatment CTC line. Specifically, we observed a generalized loss of DNA methylation in the post-treatment CTC lines, suggesting that the selective treatment pressure can alter the DNA methylome of CTCs, leading to a more hypomethylated profile. The DNA methylation differences were mainly observed at CpG-poor regions. This suggests that the epigenetic deregulation of these genomic regions may play an important role in the acquisition of therapy resistance. Typically, tumors exhibit hypomethylation of CpG-poor regions that normally comprise the majority of the methyl-cytosine content (Feinberg et al., 1988). This hypomethylation has been associated with the development of chromosomal instability (CIN), proto-oncogene expression, mismatch repair deficiency (MMRd) and the derepression of transposable elements, leading to malignant transformation of tumors (Esteller, 2008; Sheaffer et al., 2016; Besseling et al., 2023). Among these alterations, CIN has been recently proposed as one of the most relevant consequences of the generalized DNA methylation loss (Besseling et al., 2023). Hypomethylation induced CIN promotes tumor heterogeneity and cancer evolution (Besseling et al., 2023), as well as accelerates the acquisition of drug resistance through the gain of aneuploidies (Lukow et al., 2021), indicating that the DNA methylation loss observed in CTCs under selective treatment pressure could be a mechanism of therapy resistance. From a clinical point of view, analyses of hypomethylated regions in




FIGURE 4

Effect of DNA methylation changes on the transcriptional profile of the pre-treatment CTC-MCC-41 line and the post-treatment CTC-MCC-41.4 and CTC-MCC-41.5 [A-G] lines. **(A)** Association between DNA hypermethylation and gene downregulation in the pre-treatment CTC-MCC-41 line compared with all eight post-treatment CTC lines (CTC-MCC-41.4 and CTC-MCC-41.5 [A-G]). **(B,C)** Validation of the DNA methylation status of representative promoter CpGs at selected genes in the pre-treatment CTC-MCC-41 line **(B)** compared with all eight post-treatment cell lines globally and **(C)** individually. EPIC array data are expressed as percentage (%) of DNA methylation. *, p -value < 0.05 between the pre-treatment CTC-MCC-41 and the post-treatment CTC lines after EPIC array analysis; #, p -value < 0.05 between the pre-treatment CTC-MCC-41 and post-treatment cell lines after pyrosequencing analysis. HyperM, hypermethylated; Down, downregulated. Pyro, pyrosequencing; Post.4, Post-treatment CTC-MCC-41.4 line; Post.5 [A-G], Post-treatment CTC-MCC-41.5 [A-G] lines.

tumors of colon cancer patients have proven to be useful as biomarkers in different contexts (Tang et al., 2015), indicating that the discovery of hypomethylated regions in resistant CTCs could be useful as potential biomarkers of therapy resistance. In addition to CpG-poor regions, some of the DNA methylation changes that we observed in resistant CTCs were located in CpGIs, shores and promoters. In line with this, previous studies also reported DNA methylation changes at gene promoters in CRC cells associated with the development of chemotherapy resistance (Zhao et al., 2015; Wen et al., 2018).

We also identified a distinctive DNA methylation signature that clearly differentiated the pre-treatment CTC line from the post-treatment CTC lines. The genes in this signature were associated with relevant cancer pathways, including PI3K/AKT, MAPK, Wnt signaling and metabolism. The activation of PI3K/AKT and MAPK pathways are critical to induce anti-apoptosis activity and increase the aggressiveness of colon cancer cells resistant to 5-fluorouracil-based therapy (Huang et al., 2016). The Wnt signaling is one of the main pathways regulating stemness in cancer cells (Vermeulen et al., 2010) and control cell proliferation, survival, migration, and invasiveness. Alterations of this pathway are able to confer chemoresistance by maintaining the cancer stem cell population, favoring transcriptional plasticity, improving DNA damage repair, or inducing immune evasion (Moreno-Londono et al., 2023). The deregulation of metabolic pathways in cancer cells is also often

involved in the development of drug resistance. For example, uncontrolled glycolysis or abnormally activated glycolysis (e.g., Warburg effect) is usually linked to oncogenesis and chemoresistance (Liu et al., 2021). Therefore, the epigenetic deregulation of these pro-tumoral pathways in CTCs during treatment pressure could provide the CTCs with new properties to induce resistance, proliferate and escape the action of therapy. In line with our results, a recent work described the transcriptional deregulation of these pathways in the pre-treatment CTC-MCC-41 line (Smit et al., 2020) and another study identified Wnt/beta-catenin signaling as the final step of transcriptional activation in these CTCs (Zhou et al., 2023). Moreover, other authors have described the molecular deregulation of these pathways in association with proliferation and drug resistance in CRC (Stefani et al., 2021; Lin et al., 2022).

Conversely, we did not find many DNA methylation differences between the post-treatment CTC-MCC-41.4 (obtained after the last treatment) and CTC-MCC-41.5 [A-G] (obtained before the patient's death) lines. Similarly, a previous work found very few differences in gene expression among these cell lines, indicating that, in the absence of treatment pressure, the worsening of cancer is no longer linked to clonal evolution but rather to the natural progression of the disease through the replication of the CTC clones already selected under treatment (Cayrefourcq et al., 2021). However, DNA methylation presented many differences between the CTC-MCC-




FIGURE 5

Epigenetic regulation of the *AP2M1* gene in the pre-treatment CTC-MCC-41 and post-treatment CTC-MCC-41.4 and CTC-MCC-41.5 [A-G] lines. **(A)** Levels of DNA methylation at the *AP2M1* promoter and *AP2M1* expression in the pre-treatment CTC-MCC-41 line compared with all eight post-treatment cell lines. *, p -value < 0.05 for gene expression between the pre-treatment CTC-MCC-41 line and all eight post-treatment cell lines; #, p -value < 0.05 for DNA methylation between the pre-treatment CTC-MCC-41 line and all eight post-treatment cell lines. **(B)** Correlation between DNA methylation and expression levels of *AP2M1* in the pre-treatment CTC-MCC-41 and all eight post-treatment CTC lines. **(C)** DNA methylation level at the promoter and *AP2M1* expression in the pre-treatment CTC-MCC-41 line and in each post-treatment CTC line. PreT, pre-treatment CTC line; PostT, all eight post-treatment CTC lines; PostT.4, post-treatment CTC-MCC-41.4 line; PostT.5 [A-G], post-treatment CTC-MCC-41.5 [A-G] lines. Methylation (cg14663940) and expression values were determined in triplicates by pyrosequencing and RT-qPCR, respectively, and are expressed as mean \pm SD.

41.5 [ABFG] and CTC-MCC-41.5 [CDE] lines, and a DNA methylation signature could clearly differentiate these two groups. This result agrees with previous gene expression data on these CTC lines that could be used to differentiate these two groups. In particular, in this previous study, the comparison of the gene expression signatures of the two CTC-MCC-41.5 sub-groups ([ABFG] and [CDE]) revealed that *ALDOB* was upregulated in the [ABFG] group, which is mainly expressed in the liver, suggesting that the subgroup [ABFG] derives from CTCs released by liver metastases (Cayrefourcq et al., 2021). According to this, the different origin of the release of CTCs could contribute to explain the molecular differences observed between the subgroups [ABFG] and [CDE].

In this work, we also observed that DNA methylation changes in post-treatment CTC lines were associated with changes in gene expression. For example, *AP2M1*, *FKBP11*, *GALNT6*, *BDNF*, *COL9A3* and *NR4A1* showed a negative association between promoter DNA methylation and gene expression. These genes were DNA hypomethylated and upregulated in the resistant clones (CTC-MCC-41.4 and CTC-MCC-41 [A-G]), suggesting that the selective treatment pressure can restore their expression by modulating their epigenetic program. In line with this, the increased expression of these pro-tumoral genes was previously

associated with the development of therapy resistance. *BDNF* upregulation in CRC has been linked to enhanced dissemination, anoikis resistance, and chemoresistance (Ha et al., 2021). In neuroblastoma, *BDNF* expression protects cells from chemotherapy-induced apoptosis via PI3K and also increases metastasis formation via the PI3K and MAPK pathways (Jaboin et al., 2002; Hua et al., 2016). *FKBP11* expression is strongly correlated with advanced disease and poor prognosis in patients with renal cancer (Li et al., 2022), and can promote cell proliferation and tumorigenesis (Qiu et al., 2021). Moreover, *COL9A3* promotes epithelial-to-mesenchymal transition, invasion, and migration in gastric cancer (Wu et al., 2021). *GALNT6* overexpression has been associated in CRC with resistance to fluoropyrimidines and CRC cell proliferation and migration (Peng et al., 2021). This gene is also involved in the activation of the PI3K/AKT signaling pathway and in breast cancer cell migration and invasion (Liu et al., 2020). *NR4A1* is implicated in cancer progression by promoting metastasis, inflammation, proliferation, stemness and epithelial-to-mesenchymal transition and by inhibiting apoptosis (Shi et al., 2021). *AP2M1* showed an inverse correlation between DNA methylation and expression in the pre- and post-treatment CTC lines. This gene encodes a subunit of the hetero-tetrameric coat assembly protein complex 2 (AP2) that is required for vacuolar

ATPase activity and is involved in regulating protein intracellular trafficking (Liu et al., 2023). Increased *AP2M1* activity has been associated with chemotherapy resistance in several tumor types, including lymphoma (Liu et al., 2023), breast cancer and CRC (Le Duff et al., 2018). Chemotherapy acts also by inducing cancer cell senescence and growth arrest and by inhibiting proliferation. However, cancer cells may acquire new properties, escape senescence, and start to proliferate again (Le Duff et al., 2018; Guillon et al., 2019). It has been recently shown that *AP2M1* participates in the transmission of soluble signals from senescent CRC cells to promote resistance to chemotherapy (Le Duff et al., 2018), suggesting that *AP2M1* upregulation by DNA hypomethylation could be a novel mechanism by which CTCs escape from chemotherapy. In addition, the lowest DNA methylation level at the *AP2M1* promoter was observed in the resistant CTC-MCC-41.5 [ABFG] clones. Recently, it has been proposed that the CTC-MCC-41.5 [ABFG] clones are released by liver metastases (Cayrefourcq et al., 2021), suggesting that the DNA hypomethylation of the *AP2M1* promoter could be a relevant mechanism of resistance in CTCs originating from liver metastases. All these genes (*AP2M1*, *FKBP11*, *GALNT6*, *BDNF*, *COL9A3* and *NR4A1*) favor relevant features of cancer progression, indicating that their epigenetic activation in CTCs of CRC patients under treatment could be a key event for the development of therapy resistance and cancer progression. Among the clinical applications of DNA methylation in cancer, the evaluation of this epigenetic mark in CTCs has been recently suggested as a non-invasive biomarker for monitoring the evolution of the disease during treatment and detecting resistance in lung cancer (Ntzifa et al., 2021). In line with this, analysis of CTCs to monitor the loss of methylation in the genes identified in our work could be useful in the clinic to detect the development of therapy resistance and the progression of the disease in CRC patients. This potential clinical application should be confirmed in future clinical studies.

Loss of methylation in tumors is able to restore the expression of oncogenes that had been epigenetically silenced (Lu et al., 2020). The action of drugs directed to oncogenic proteins represent a key strategy to fight against cancer. For example, the use of therapeutic targets against EGFR (cetuximab) and VEGF (bevacizumab) has shown efficacy to treat mCRC patients (Culy, 2005; Tabernero et al., 2007). Importantly, targeting oncogenes in CTCs is able to reduce the tumoral properties of these cells. A recent *in vitro* study demonstrated that AKT and mTOR inhibitors are able to reduce the growth of CTCs (Smit et al., 2020). In our study, loss of methylation in resistant CTCs restored the expression of several genes with pro-tumoral properties, suggesting that targeting these genes in CTCs could be a new approach to combat the acquisition of therapy resistance and progression in colon cancer.

In summary, this study shows that therapy pressure can induce a global reprogramming in the DNA methylation profile of CTCs, leading to a more hypomethylated profile. Loss of methylation in CTCs during selective treatment pressure could represent a novel mechanism for inducing treatment resistance. Therapy-resistant CTCs also showed a distinctive DNA methylation signature enriched in relevant cancer pathways related to the acquisition of therapy resistance and tumor progression. Several epigenetically deregulated genes associated with therapy resistance in CTCs were

identified, particularly *AP2M1*. Loss of methylation in CTCs could be a potential non-invasive biomarker in CRC patients for monitoring the effectiveness of treatment and the development of resistance, which should be evaluated and confirmed in future clinical studies. Thus, the genes identified in this study represent new potential biomarkers of resistance and therapeutic targets that could contribute to the development of new clinical tools and therapies for CRC patients. The findings of this work open new avenues for future studies that evaluate the reprogramming of CTCs as a mechanism of therapy resistance in cancer, with potential biological and clinical implications for the progression of the disease.

Data availability statement

The data presented in the study are deposited in the Gene Expression Omnibus (GEO) repository, accession number GSE239549.

Ethics statement

Ethical approval was not required for the studies involving humans because in this study, we used human CTC lines that were generated and characterized in a previous study by the group of CA-P (Soler A et al. Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes. *Sci Rep*, 2018. 29;8(1):15931. doi: 10.1038/s41598-018-34365-z. PMID: 30374140) in accordance with the World Medical Association Declaration of Helsinki and the guidelines for experimentation with humans by the Bioethical committee “Sud Méditerranée III”. The experimental protocol was approved (Approval reference No. 2011-A01130-41) by the Bioethical committee “Sud Méditerranée III”. These CTC lines were kindly provided for this study by CA-P. The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired from primarily isolated as part of your previous study for which ethical approval was obtained. Written informed consent to participate in this study was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and the institutional requirements.

Author contributions

AB-C: Formal Analysis, Investigation, Methodology, Writing—original draft. NC-F: Formal Analysis, Methodology, Writing—review and editing. LC: Writing—review and editing, Methodology. AR-C: Methodology, Writing—review and editing. LR: Writing—review and editing, Resources. RL-L: Conceptualization, Resources, Writing—review and editing. CA-P: Conceptualization, Formal Analysis, Resources, Supervision, Writing—original draft, Writing—review and editing. AD-L: Conceptualization, Formal Analysis, Funding acquisition, Resources, Supervision, Writing—original draft, Writing—review and editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by the ISCIII (PI18/00307) and the European Regional Development Fund (FEDER), and by the Liquid Biopsy Crowdfunding campaign organized by ONCOMET in 2017. AB-C is funded by a predoctoral contract PFIS (FI19/00240) from “Instituto de Salud Carlos III” (ISCIII) co-funded by “Fondo Social Europeo” (FSE). NC-F is funded by a predoctoral contract from “Xunta de Galicia” (IN606A-2020/004). AR-C is supported by the Roche-Chus Joint Unit (IN853B 2018/03) funded by GAIN, “Axencia Galega de Innovación (GAIN), Vicepresidencia Segunda e Consellería de Economía, Empresa e Innovación”. LR is funded by a contract “Miguel Servet” from ISCIII (CP20/00129). CA-P is supported by funding from the European Union Horizon 2020 Research and Innovation program under the Marie Skłodowska-Curie grant agreement No. 765492, by The National Institute of Cancer (INCa, <http://www.e-cancer.fr>), and the ERA-NET TRANSCAN 2 JTC 2016 PROLIPSY, la Fondation ARC pour la Recherche sur le cancer and les Fonds de dotation AFER pour la recherche médicale. AD-L was funded by a contract “Juan Rodés” (JR17/00016) from “Instituto de Salud Carlos III” (ISCIII) and by Servicio Galego de Saúde (SERGAS).

Acknowledgments

We would like to thank all donors who participated in the Liquid Biopsy Crowdfunding campaign organized by ONCOMET in 2017 for their contribution to support this work.

References

- Aranda, E., Vieitez, J. M., Gomez-Espana, A., Gil Calle, S., Salud-Salvia, A., Grana, B., et al. (2020). FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥ 3 circulating tumour cells: the randomised phase III VISNÚ-1 trial. *ESMO Open* 5 (6), e000944. doi:10.1136/esmoopen-2020-000944
- Besselink, N., Keijer, J., Vermeulen, C., Boymans, S., de Ridder, J., van Hoeck, A., et al. (2023). The genome-wide mutational consequences of DNA hypomethylation. *Sci. Rep.* 13 (1), 6874. doi:10.1038/s41598-023-33932-3
- Billir, L. H., and Schrag, D. (2021). Diagnosis and treatment of metastatic colorectal cancer: a review. *JAMA* 325 (7), 669–685. doi:10.1001/jama.2021.0106
- Cayrefourcq, L., Mazard, T., Joosse, S., Solassol, J., Ramos, J., Assenat, E., et al. (2015). Establishment and characterization of a cell line from human circulating colon cancer cells. *Cancer Res.* 75 (5), 892–901. doi:10.1158/0008-5472.CAN-14-2613
- Cayrefourcq, L., Thomas, F., Mazard, T., Assenat, E., Assou, S., and Alix-Panabieres, C. (2021). Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones. *Mol. Cancer* 20 (1), 30. doi:10.1186/s12943-021-01326-6
- Chimonidou, M., Strati, A., Tzitzira, A., Sotiropoulou, G., Malamos, N., Georgoulas, V., et al. (2011). DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. *Clin. Chem.* 57 (8), 1169–1177. doi:10.1373/clinchem.2011.165902
- Culy, C. (2005). Bevacizumab: antiangiogenic cancer therapy. *Drugs Today (Barc)* 41 (1), 23–36. doi:10.1358/dot.2005.41.1.875776
- Diaz-Lagares, A., Crujeiras, A. B., Lopez-Serra, P., Soler, M., Setien, F., Goyal, A., et al. (2016). Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer. *Proc. Natl. Acad. Sci. U. S. A.* 113 (47), E7535–E7544–E7544. doi:10.1073/pnas.1608585113
- Esteller, M. (2008). Epigenetics in cancer. *N. Engl. J. Med.* 358 (11), 1148–1159. doi:10.1056/NEJMr072067
- Feinberg, A. P., Gehrke, C. W., Kuo, K. C., and Ehrlich, M. (1988). Reduced genomic 5-methylcytosine content in human colonic neoplasia. *Cancer Res.* 48 (5), 1159–1161.

Conflict of interest

RL-L has received honoraria for participation in Advisory Boards from Roche, AstraZeneca, Merck, Merck Sharp & Dohme, Bayer, Bristol-Myers Squibb, Novartis, Janssen, Lilly, Pfizer, and Leo; travel, accommodations, and expenses from PharmaMar, Roche, Bristol-Myers Squibb, and Pierre Fabre; research funding from Roche and Merck; and is co-founder and shareholder in Nasasbiotech, S.L., Mtrap Inc. CA-P. has received honoraria from Menarini.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fcell.2023.1291179/full#supplementary-material>

- Gkoutela, S., Castro-Giner, F., Szczerba, B. M., Vetter, M., Landin, J., Scherrer, R., et al. (2019). Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. *Cell* 176 (1–2), 98–112. doi:10.1016/j.cell.2018.11.046
- Guillon, J., Petit, C., Toutain, B., Guette, C., Lelievre, E., and Coqueret, O. (2019). Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity. *Cell Cycle* 18 (19), 2385–2397. doi:10.1080/15384101.2019.1652047
- Ha, C. T., Cheng, C. Y., Zheng, M. Y., Hsu, T. H., Miao, C. C., Lee, C. J., et al. (2021). ID4 predicts poor prognosis and promotes BDNF-mediated oncogenesis of colorectal cancer. *Carcinogenesis* 42 (7), 951–960. doi:10.1093/carcin/bgab037
- Hanahan, D. (2022). Hallmarks of cancer: new dimensions. *Cancer Discov.* 12 (1), 31–46. doi:10.1158/2159-8290.CD-21-1059
- Hua, Z., Gu, X., Dong, Y., Tan, F., Liu, Z., Thiele, C. J., et al. (2016). PI3K and MAPK pathways mediate the BDNF/TrkB-increased metastasis in neuroblastoma. *Tumour Biol.* 37 (12), 16227–16236. doi:10.1007/s13277-016-5433-z
- Huang, W. S., Hsieh, M. C., Huang, C. Y., Kuo, Y. H., Tung, S. Y., Shen, C. H., et al. (2016). The association of CXCR4 receptor 4 mediated signaling pathway with oxaliplatin-resistant human colorectal cancer cells. *PLoS One* 11 (9), e0159927. doi:10.1371/journal.pone.0159927
- Jaboin, J., Kim, C. J., Kaplan, D. R., and Thiele, C. J. (2002). Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway. *Cancer Res.* 62 (22), 6756–6763.
- Le Duff, M., Gouju, J., Jonchere, B., Guillon, J., Toutain, B., Boissard, A., et al. (2018). Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in response to chemotherapy. *Cell Death Dis.* 9 (2), 199. doi:10.1038/s41419-017-0209-y
- Li, K., Li, Y., Lyu, Y., Tan, L., Zheng, X., Jiang, H., et al. (2022). Development of a phagocytosis-dependent gene signature to predict prognosis and response to checkpoint inhibition in clear-cell renal cell carcinoma. *Front. Immunol.* 13, 853088. doi:10.3389/fimmu.2022.853088
- Lin, J., Xia, L., Oyang, L., Liang, J., Tan, S., Wu, N., et al. (2022). The POU2F1-ALDOA axis promotes the proliferation and chemoresistance of colon cancer cells by

- enhancing glycolysis and the pentose phosphate pathway activity. *Oncogene* 41 (7), 1024–1039. doi:10.1038/s41388-021-02148-y
- Liu, C., Jin, Y., and Fan, Z. (2021). The mechanism of warburg effect-induced chemoresistance in cancer. *Front. Oncol.* 11, 698023. doi:10.3389/fonc.2021.698023
- Liu, C., Li, Z., Xu, L., Shi, Y., Zhang, X., Shi, S., et al. (2020). GALNT6 promotes breast cancer metastasis by increasing mucin-type O-glycosylation of α2M. *Aging (Albany NY)* 12 (12), 11794–11811. doi:10.18632/aging.103349
- Liu, X., Zhao, X., Yang, J., Wang, H., Piao, Y., and Wang, L. (2023). High expression of AP2M1 correlates with worse prognosis by regulating immune microenvironment and drug resistance to R-CHOP in diffuse large B cell lymphoma. *Eur. J. Haematol.* 110 (2), 198–208. doi:10.1111/ejh.13895
- Lu, J., Tan, T., Zhu, L., Dong, H., and Xian, R. (2020). Hypomethylation causes MIR21 overexpression in tumors. *Mol. Ther. Oncolytics* 18, 47–57. doi:10.1016/j.omto.2020.05.011
- Lukow, D. A., Sausville, E. L., Suri, P., Chunduri, N. K., Wieland, A., Leu, J., et al. (2021). Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies. *Dev. Cell.* 56 (17), 2427–2439.e4. doi:10.1016/j.devcel.2021.07.009
- Luo, M., Yang, X., Chen, H. N., Nice, E. C., and Huang, C. (2021). Drug resistance in colorectal cancer: an epigenetic overview. *Biochim. Biophys. Acta Rev. Cancer* 1876 (2), 188623. doi:10.1016/j.bbcan.2021.188623
- Moran, S., Arribas, C., and Esteller, M. (2016). Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences. *Epigenomics* 8 (3), 389–399. doi:10.2217/epi.15.114
- Moreno-Londono, A. P., Castaneda-Patlan, M. C., Sarabia-Sanchez, M. A., Macias-Silva, M., and Robles-Flores, M. (2023). Canonical Wnt pathway is involved in chemoresistance and cell cycle arrest induction in colon cancer cell line spheroids. *Int. J. Mol. Sci.* 24 (6), 5252. doi:10.3390/ijms24065252
- Moutinho, C., Martinez-Cardus, A., Santos, C., Navarro-Perez, V., Martinez-Balibrea, E., Musulen, E., et al. (2014). Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. *J. Natl. Cancer Inst.* 106 (1), djt322. doi:10.1093/jnci/djt322
- Muller, F., Scherer, M., Assenov, Y., Lutsik, P., Walter, J., Lengauer, T., et al. (2019). RnBeads 2.0: comprehensive analysis of DNA methylation data. *Genome Biol.* 20 (1), 55. doi:10.1186/s13059-019-1664-9
- Narayan, S., Raza, A., Mahmud, I., Koo, N., Garrett, T. J., Law, M. E., et al. (2022). Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A. *iScience* 25 (7), 104518. doi:10.1016/j.isci.2022.104518
- Ntzifa, A., Londra, D., Rampias, T., Kotsakis, A., Georgoulas, V., and Lianidou, E. (2021). DNA methylation analysis in plasma cell-free DNA and paired CTCs of NSCLC patients before and after osimertinib treatment. *Cancers (Basel)* 13 (23), 5974. doi:10.3390/cancers13235974
- Peng, X., Chen, X., Zhu, X., and Chen, L. (2021). GALNT6 knockdown inhibits the proliferation and migration of colorectal cancer cells and increases the sensitivity of cancer cells to 5-FU. *J. Cancer* 12 (24), 7413–7421. doi:10.7150/jca.62332
- Qiu, L., Liu, H., Wang, S., Dai, X. H., Shang, J. W., Lian, X. L., et al. (2021). FKBP11 promotes cell proliferation and tumorigenesis via p53-related pathways in oral squamous cell carcinoma. *Biochem. Biophys. Res. Commun.* 559, 183–190. doi:10.1016/j.bbrc.2021.04.096
- Rodriguez-Casanova, A., Costa-Fraga, N., Bao-Caamano, A., Lopez-Lopez, R., Muinelo-Romay, L., and Diaz-Lagares, A. (2021). Epigenetic landscape of liquid biopsy in colorectal cancer. *Front. Cell. Dev. Biol.* 9, 622459. doi:10.3389/fcell.2021.622459
- Sawant, M., Wilson, A., Sridaran, D., Mahajan, K., O'Connor, C. J., Hagemann, I. S., et al. (2023). Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4/6 inhibitor. *Oncogene* 42 (29), 2263–2277. doi:10.1038/s41388-023-02747-x
- Sheaffer, K. L., Elliott, E. N., and Kaestner, K. H. (2016). DNA hypomethylation contributes to genomic instability and intestinal cancer initiation. *Cancer Prev. Res. (Phila)* 9 (7), 534–546. doi:10.1158/1940-6207.CAPR-15-0349
- Shi, Z., To, S. K. Y., Zhang, S., Deng, S., Artemenko, M., Zhang, M., et al. (2021). Hypoxia-induced Nur77 activates PI3K/Akt signaling via suppression of Dicer/let-7i-5p to induce epithelial-to-mesenchymal transition. *Theranostics* 11 (7), 3376–3391. doi:10.7150/thno.52190
- Smit, D. J., Cayrefourcq, L., Haider, M. T., Hinz, N., Pantel, K., Alix-Panabieres, C., et al. (2020). High sensitivity of circulating tumor cells derived from a colorectal cancer patient for dual inhibition with AKT and mTOR inhibitors. *Cells* 9 (9), 2129. doi:10.3390/cells9092129
- Soler, A., Cayrefourcq, L., Mazard, T., Babayan, A., Lamy, P. J., Assou, S., et al. (2018). Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes. *Sci. Rep.* 8 (1), 15931. doi:10.1038/s41598-018-34365-z
- Stefani, C., Mircescu, D., Stanescu, S., II, Nica, R. I., Greabu, M., Totan, A. R., et al. (2021). Growth factors, PI3K/AKT/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now? *Int. J. Mol. Sci.* 22 (19), 10260. doi:10.3390/ijms221910260
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* 71 (3), 209–249. doi:10.3322/caac.21660
- Tabas-Madrid, D., Nogales-Cadenas, R., and Pascual-Montano, A. (2012). GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics. *Nucleic Acids Res.* 40, W478–W483. Web Server issue. doi:10.1093/nar/gks402
- Taberno, J., Van Cutsem, E., Diaz-Rubio, E., Cervantes, A., Humblet, Y., Andre, T., et al. (2007). Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. *J. Clin. Oncol.* 25 (33), 5225–5232. doi:10.1200/JCO.2007.13.2183
- Tan, X., Zhang, S., Gao, H., He, W., Xu, M., Wu, Q., et al. (2019). Hypermethylation of the PTTG1P promoter leads to low expression in early-stage non-small cell lung cancer. *Oncol. Lett.* 18 (2), 1278–1286. doi:10.3892/ol.2019.10400
- Tang, J. T., Wang, Z. H., and Fang, J. Y. (2015). Assessing the potential value of long interspersed element-1 hypomethylation in colorectal cancer: evidence from retrospective studies. *Onco Targets Ther.* 8, 3265–3276. doi:10.2147/OTT.S91941
- Vermeulen, L., De Sousa, E. M. F., van der Heijden, M., Cameron, K., de Jong, J. H., Borovski, T., et al. (2010). Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. *Nat. Cell. Biol.* 12 (5), 468–476. doi:10.1038/ncb2048
- Wen, S., Wang, X., Wang, Y., Shen, J., Pu, J., Liang, H., et al. (2018). Nucleoside diphosphate kinase 2 confers acquired 5-fluorouracil resistance in colorectal cancer cells. *Artif. Cells Nanomed Biotechnol.* 46 (Suppl. 1), 896–905. doi:10.1080/21691401.2018.1439835
- Wu, X., Wang, H., Zhu, D., Chai, Y., Wang, J., Dai, W., et al. (2021). USP3 promotes gastric cancer progression and metastasis by deubiquitination-dependent COL9A3/COL6A5 stabilisation. *Cell. Death Dis.* 13 (1), 10. doi:10.1038/s41419-021-04460-7
- Zhao, X. Q., Zhang, Y. F., Xia, Y. F., Zhou, Z. M., and Cao, Y. Q. (2015). Promoter demethylation of nuclear factor-erythroid 2-related factor 2 gene in drug-resistant colon cancer cells. *Oncol. Lett.* 10 (3), 1287–1292. doi:10.3892/ol.2015.3468
- Zhou, K., Cheong, J. E., Krishnaji, S. T., Ghalali, A., Fu, H., Sui, L., et al. (2023). Inhibition of Wnt signaling in colon cancer cells via an oral drug that facilitates TNIK degradation. *Mol. Cancer Ther.* 22 (1), 25–36. doi:10.1158/1535-7163.MCT-21-0801